Ruxolitinib Cream Improves Clinical Outcomes in Moderate-to-Severe Non-Atopic Chronic Hand Eczema: Responses by Subtype
Chronic hand eczema (CHE) is characterized by persistent or recurrent inflammatory lesions on the hands and wrists. Ruxolitinib (Janus kinase [JAK]1/JAK2 inhibitor) cream has demonstrated efficacy in atopic and nonatopic hand eczema. In a phase 2 study in adults with moderate-to-severe nonatopic CHE (NCT05906628), 1.5%...